Covid-19: Update on neutralising monoclonal antibody treatment

  • Home
  • News
  • Covid-19: Update on neutralising monoclonal antibody treatment
NCL Wide
Add to CPD

In June 2021, NHS England and NHS Improvement wrote to all ICSs about a potential new treatment for a small section of the population who test positive for Covid-19. This new treatment is an antibody infusion called neutralising monoclonal antibodies (nMAbs).

Changes to the existing policy, made on 4 November, meant that Ronapreve was recommended to be available as a treatment option for Covid-19 for hospitalised adults and children (aged 12 years and above) in accordance with the criteria set out in the attached policy. 

As way of update for all in NCL CCG, the policy also now includes the use in hospitalised patients for those admitted for a reason other than Covid. Therefore: 

  • patients hospitalised for acute Covid-19 illness (August 2021)
  • patients with hospital-onset Covid-19 (November 2021)

Acute hospitals across NCL have an MDT arrangement in place that will enable case by case discussion of each patient if required. ‘Buddying’ arrangements are also agreed between the acute sites and the mental health and community providers where transfer arrangements may be required.

The CCG is working on having in place our NCL ambulatory unit at UCLH which will deliver the intravenous treatments to those who are resident in our community. Indications are that once the new policy for the community cohort has been agreed, this should commence service during December. 

Eligibility for nMAB treatment for those patients classified as very high risk of severe illness from Covid-19, will be agreed nationally and referral pathways will be organised in a way that should not impact on GP workload at this difficult time.

Updated information for GPs will be shared as soon as it is available.

Interim Clinical Commissioning Policy: Casirivimab and Imdevimab in the treatment of COVID-19 in hospitalised patients (GOV.UK)

Expiry date: Feb 1st, 2022